Genmab Logo

Genmab

ISIN

DK0010272202

Ticker

GMAB

Sector

Health Care

Sub-Industry

Biotechnology

Country

Denmark

Year Founded

1999

About Genmab

Company Description

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Our headquarter is in Copenhagen, Denmark with sites in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan.

We are the creators of three marketed products* and have a broad clinical and pre-clinical product pipeline. Genmab's technology consists of validated and proprietary next-generation antibody platforms - DuoBody® for generation of bispecific antibodies; HexaBody®, which creates effector-function enhanced antibodies; HexElect®, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency; and DuoHexaBody®, which enhances the potential potency of bispecific antibodies through hexamerization.

Headquarters

Kalvebod Brygge 43
1560, Copenhagen
Denmark

Financial statements

Download as Excel
Line item in (dkk) 01.01.2019 01.01.2020 01.01.2021 01.07.2021 01.10.2021 01.01.2022 01.04.2022 01.07.2022 01.10.2022 01.01.2023 01.02.2023 01.04.2023 01.07.2023 01.01.2024 01.04.2024
Assets N/A N/A 21,143,000,000.00 N/A N/A 24,627,000,000.00 N/A 27,476,000,000.00 30,686,000,000.00 30,278,000,000.00 35,289,000,000.00 N/A 31,978,000,000.00 N/A 36,680,000,000.00
Noncurrent Assets N/A N/A 2,352,000,000.00 N/A N/A 1,891,000,000.00 N/A 1,985,000,000.00 1,947,000,000.00 1,901,000,000.00 2,150,000,000.00 N/A 2,229,000,000.00 N/A 2,311,000,000.00
Property Plant And Equipment N/A N/A 453,000,000.00 N/A N/A 621,000,000.00 N/A 684,000,000.00 741,000,000.00 799,000,000.00 955,000,000.00 N/A 908,000,000.00 N/A 937,000,000.00
Intangible Assets Other Than Goodwill N/A N/A 338,000,000.00 N/A N/A 254,000,000.00 N/A 216,000,000.00 200,000,000.00 146,000,000.00 101,000,000.00 N/A 129,000,000.00 N/A 23,000,000.00
Noncurrent Receivables N/A N/A 20,000,000.00 N/A N/A 27,000,000.00 N/A 66,000,000.00 39,000,000.00 48,000,000.00 62,000,000.00 N/A 31,000,000.00 N/A 63,000,000.00
Deferred Tax Assets N/A N/A 177,000,000.00 N/A N/A 264,000,000.00 N/A 264,000,000.00 264,000,000.00 252,000,000.00 212,000,000.00 N/A 252,000,000.00 N/A 212,000,000.00
Noncurrent Investments Other Than Investments Accounted For Using Equity Method N/A N/A 1,081,000,000.00 N/A N/A 371,000,000.00 N/A 201,000,000.00 155,000,000.00 133,000,000.00 134,000,000.00 140,000,000.00 183,000,000.00 N/A 153,000,000.00
Current Assets N/A N/A 18,791,000,000.00 N/A N/A 22,736,000,000.00 N/A 25,491,000,000.00 28,739,000,000.00 28,377,000,000.00 33,139,000,000.00 N/A 29,749,000,000.00 N/A 34,369,000,000.00
Inventories N/A N/A N/A N/A N/A N/A N/A N/A N/A 0.00 57,000,000.00 N/A 51,000,000.00 N/A 106,000,000.00
Trade And Other Current Receivables N/A N/A 2,463,000,000.00 N/A N/A 3,367,000,000.00 N/A 3,876,000,000.00 4,951,000,000.00 5,910,000,000.00 4,947,000,000.00 N/A 4,690,000,000.00 N/A 4,679,000,000.00
Current Tax Assets Current N/A N/A 249,000,000.00 N/A N/A 31,000,000.00 N/A 0.00 0.00 143,000,000.00 N/A N/A 124,000,000.00 N/A N/A
Current Financial Assets At Fair Value Through Profit Or Loss Mandatorily Measured At Fair Value N/A N/A 8,819,000,000.00 N/A N/A 10,381,000,000.00 N/A 11,799,000,000.00 13,411,000,000.00 12,431,000,000.00 13,268,000,000.00 12,256,000,000.00 14,010,000,000.00 N/A 14,914,000,000.00
Cash and cash equivalents 533,000,000.00 3,552,000,000.00 7,260,000,000.00 9,477,000,000.00 8,729,000,000.00 8,957,000,000.00 9,071,000,000.00 9,816,000,000.00 10,377,000,000.00 9,893,000,000.00 14,867,000,000.00 12,288,000,000.00 10,874,000,000.00 14,867,000,000.00 14,670,000,000.00
Balances With Banks N/A 2,884,000,000.00 5,054,000,000.00 6,908,000,000.00 8,542,000,000.00 8,661,000,000.00 8,512,000,000.00 8,810,000,000.00 9,082,000,000.00 9,299,000,000.00 N/A 11,583,000,000.00 10,240,000,000.00 N/A 13,773,000,000.00
Shortterm Investments Classified As Cash Equivalents N/A 668,000,000.00 2,206,000,000.00 2,569,000,000.00 187,000,000.00 296,000,000.00 559,000,000.00 1,006,000,000.00 1,295,000,000.00 594,000,000.00 N/A 705,000,000.00 634,000,000.00 N/A 897,000,000.00
Equity And Liabilities N/A N/A 21,143,000,000.00 N/A N/A 24,627,000,000.00 N/A 27,476,000,000.00 30,686,000,000.00 30,278,000,000.00 35,289,000,000.00 N/A 31,978,000,000.00 N/A 36,680,000,000.00
Equity 8,014,000,000.00 14,048,000,000.00 19,121,000,000.00 20,252,000,000.00 21,285,000,000.00 22,196,000,000.00 N/A 24,482,000,000.00 26,657,000,000.00 27,441,000,000.00 31,610,000,000.00 27,015,000,000.00 28,755,000,000.00 31,610,000,000.00 32,497,000,000.00
Issued Capital N/A N/A 66,000,000.00 N/A N/A 66,000,000.00 N/A 66,000,000.00 66,000,000.00 66,000,000.00 66,000,000.00 N/A 66,000,000.00 N/A 66,000,000.00
Retained Earnings N/A N/A 7,107,000,000.00 N/A N/A 10,020,000,000.00 N/A 12,243,000,000.00 14,299,000,000.00 14,968,000,000.00 19,023,000,000.00 N/A 16,165,000,000.00 N/A 19,803,000,000.00
Share Premium N/A N/A 11,894,000,000.00 N/A N/A 12,029,000,000.00 N/A 12,063,000,000.00 12,141,000,000.00 12,309,000,000.00 12,461,000,000.00 N/A 12,412,000,000.00 N/A 12,520,000,000.00
Other Reserves N/A N/A 54,000,000.00 N/A N/A 81,000,000.00 N/A 110,000,000.00 151,000,000.00 98,000,000.00 60,000,000.00 N/A 112,000,000.00 N/A 108,000,000.00
Liabilities N/A N/A 2,022,000,000.00 N/A N/A 2,431,000,000.00 N/A 2,994,000,000.00 4,029,000,000.00 2,837,000,000.00 3,679,000,000.00 N/A 3,223,000,000.00 N/A 4,183,000,000.00
Noncurrent Liabilities N/A N/A 769,000,000.00 N/A N/A 863,000,000.00 N/A 1,050,000,000.00 1,041,000,000.00 1,014,000,000.00 1,195,000,000.00 N/A 1,230,000,000.00 N/A 1,424,000,000.00
Noncurrent Provisions N/A N/A 4,000,000.00 N/A N/A 13,000,000.00 N/A 7,000,000.00 7,000,000.00 N/A N/A N/A N/A N/A N/A
Noncurrent Deferred Income Including Noncurrent Contract Liabilities N/A N/A N/A N/A N/A 487,000,000.00 N/A N/A 480,000,000.00 480,000,000.00 480,000,000.00 480,000,000.00 480,000,000.00 N/A 480,000,000.00
Other Noncurrent Payables N/A N/A 1,000,000.00 N/A N/A 13,000,000.00 N/A 2,000,000.00 4,000,000.00 11,000,000.00 35,000,000.00 29,000,000.00 29,000,000.00 N/A 26,000,000.00
Current Liabilities N/A N/A 1,253,000,000.00 N/A N/A 1,568,000,000.00 N/A 1,944,000,000.00 2,988,000,000.00 1,823,000,000.00 2,484,000,000.00 N/A 1,993,000,000.00 N/A 2,759,000,000.00
Current Provisions N/A N/A N/A N/A N/A 0.00 N/A 6,000,000.00 6,000,000.00 N/A N/A N/A N/A N/A N/A
Current Deferred Income Including Current Contract Liabilities N/A N/A N/A N/A N/A 26,000,000.00 N/A N/A 33,000,000.00 33,000,000.00 33,000,000.00 33,000,000.00 33,000,000.00 N/A 33,000,000.00
Other Current Payables N/A N/A 1,185,000,000.00 N/A N/A 1,480,000,000.00 N/A 1,575,000,000.00 1,922,000,000.00 1,716,000,000.00 2,307,000,000.00 1,833,000,000.00 1,878,000,000.00 N/A 2,512,000,000.00
Current Tax Liabilities Current N/A N/A N/A N/A N/A 0.00 N/A 257,000,000.00 948,000,000.00 N/A 54,000,000.00 N/A N/A N/A 122,000,000.00
Line item in (dkk) 01.01.2019/
01.01.2020
01.01.2020/
01.01.2021
01.01.2021/
01.07.2021
01.01.2021/
01.10.2021
01.01.2021/
01.01.2022
01.04.2021/
01.07.2021
01.07.2021/
01.10.2021
01.01.2022/
01.04.2022
01.01.2022/
01.07.2022
01.01.2022/
01.10.2022
01.01.2022/
01.01.2023
01.04.2022/
01.07.2022
01.07.2022/
01.10.2022
01.01.2023/
01.04.2023
01.01.2023/
01.07.2023
01.04.2023/
01.07.2023
01.01.2024/
01.04.2024
Revenue 5,366,000,000.00 10,111,000,000.00 3,553,000,000.00 5,863,000,000.00 8,482,000,000.00 1,972,000,000.00 2,310,000,000.00 N/A 5,281,000,000.00 9,368,000,000.00 14,595,000,000.00 3,162,000,000.00 4,087,000,000.00 2,834,000,000.00 7,052,000,000.00 4,198,000,000.00 4,143,000,000.00
Profit Loss From Operating Activities 2,638,000,000.00 6,313,000,000.00 1,319,000,000.00 2,209,000,000.00 3,018,000,000.00 787,000,000.00 890,000,000.00 N/A 1,761,000,000.00 3,692,000,000.00 6,357,000,000.00 1,247,000,000.00 1,931,000,000.00 417,000,000.00 1,934,000,000.00 1,497,000,000.00 801,000,000.00
Finance Income 228,000,000.00 1,149,000,000.00 700,000,000.00 1,211,000,000.00 1,667,000,000.00 65,000,000.00 511,000,000.00 N/A 1,879,000,000.00 3,432,000,000.00 1,358,000,000.00 1,442,000,000.00 1,553,000,000.00 284,000,000.00 527,000,000.00 243,000,000.00 928,000,000.00
Finance Costs 7,000,000.00 1,558,000,000.00 173,000,000.00 403,000,000.00 702,000,000.00 430,000,000.00 230,000,000.00 N/A 539,000,000.00 751,000,000.00 680,000,000.00 200,000,000.00 212,000,000.00 435,000,000.00 452,000,000.00 17,000,000.00 13,000,000.00
Profit Loss Before Tax 2,859,000,000.00 5,904,000,000.00 1,846,000,000.00 3,017,000,000.00 3,983,000,000.00 422,000,000.00 1,171,000,000.00 N/A 3,101,000,000.00 6,373,000,000.00 7,035,000,000.00 2,489,000,000.00 3,272,000,000.00 266,000,000.00 2,009,000,000.00 1,723,000,000.00 1,716,000,000.00
Income Tax Expense Continuing Operations 693,000,000.00 1,146,000,000.00 444,000,000.00 725,000,000.00 975,000,000.00 116,000,000.00 281,000,000.00 N/A 745,000,000.00 1,435,000,000.00 1,513,000,000.00 598,000,000.00 690,000,000.00 56,000,000.00 426,000,000.00 366,000,000.00 391,000,000.00
Profit (loss) 2,166,000,000.00 4,758,000,000.00 1,402,000,000.00 2,292,000,000.00 3,008,000,000.00 306,000,000.00 890,000,000.00 465,000,000.00 2,356,000,000.00 4,938,000,000.00 5,522,000,000.00 1,891,000,000.00 2,582,000,000.00 226,000,000.00 1,583,000,000.00 1,357,000,000.00 1,325,000,000.00
Line item in (dkk) 01.01.2019 01.01.2020 01.01.2021 01.07.2021 01.10.2021 01.01.2022 01.04.2022 01.07.2022 01.10.2022 01.01.2023 01.04.2023 01.07.2023 01.02.2023 01.01.2024 01.04.2024
Profit (loss) N/A 2,166,000,000.00 4,758,000,000.00 306,000,000.00 890,000,000.00 3,008,000,000.00 465,000,000.00 1,891,000,000.00 2,582,000,000.00 5,522,000,000.00 226,000,000.00 1,357,000,000.00 N/A N/A 1,325,000,000.00
Other Adjustments For Noncash Items N/A 291,000,000.00 459,000,000.00 227,000,000.00 376,000,000.00 526,000,000.00 N/A 347,000,000.00 574,000,000.00 801,000,000.00 187,000,000.00 423,000,000.00 N/A N/A 323,000,000.00
Cash Flows From Used In Operations N/A 1,711,000,000.00 7,759,000,000.00 1,441,000,000.00 1,829,000,000.00 2,774,000,000.00 N/A 1,929,000,000.00 3,812,000,000.00 5,228,000,000.00 3,461,000,000.00 3,698,000,000.00 N/A N/A 1,543,000,000.00
Interest Paid Classified As Operating Activities N/A N/A N/A N/A 0.00 N/A N/A 1,000,000.00 1,000,000.00 N/A N/A 0.00 N/A N/A N/A
Interest Received Classified As Operating Activities N/A 111,000,000.00 170,000,000.00 107,000,000.00 169,000,000.00 208,000,000.00 N/A 80,000,000.00 169,000,000.00 283,000,000.00 179,000,000.00 384,000,000.00 N/A N/A 301,000,000.00
Cash Flows From Used In Operating Activities N/A 1,326,000,000.00 6,433,000,000.00 1,540,000,000.00 1,987,000,000.00 2,228,000,000.00 N/A 1,546,000,000.00 3,514,000,000.00 3,912,000,000.00 3,235,000,000.00 3,671,000,000.00 N/A N/A 1,513,000,000.00
Purchase Of Property Plant And Equipment Classified As Investing Activities N/A 79,000,000.00 307,000,000.00 107,000,000.00 184,000,000.00 252,000,000.00 N/A 125,000,000.00 207,000,000.00 317,000,000.00 104,000,000.00 201,000,000.00 N/A N/A 28,000,000.00
Purchase Of Intangible Assets Classified As Investing Activities N/A 32,000,000.00 0.00 N/A N/A 0.00 N/A 0.00 N/A N/A N/A 10,000,000.00 N/A N/A N/A
Cash Flows From Used In Investing Activities N/A -1,983,000,000.00 -2,351,000,000.00 966,000,000.00 -655,000,000.00 -961,000,000.00 N/A -1,243,000,000.00 -2,625,000,000.00 -2,761,000,000.00 -13,000,000.00 -1,848,000,000.00 N/A N/A -1,441,000,000.00
Proceeds From Issuing Shares N/A 3,873,000,000.00 0.00 N/A N/A 0.00 N/A N/A N/A N/A N/A N/A N/A N/A N/A
Payments To Acquire Or Redeem Entitys Shares N/A 0.00 0.00 437,000,000.00 447,000,000.00 447,000,000.00 N/A 211,000,000.00 908,000,000.00 908,000,000.00 543,000,000.00 564,000,000.00 N/A N/A 545,000,000.00
Payments Of Lease Liabilities Classified As Financing Activities N/A 31,000,000.00 44,000,000.00 29,000,000.00 50,000,000.00 58,000,000.00 N/A 30,000,000.00 47,000,000.00 73,000,000.00 21,000,000.00 50,000,000.00 N/A N/A 24,000,000.00
Cash Flows From Used In Financing Activities N/A 3,660,000,000.00 71,000,000.00 -460,000,000.00 -436,000,000.00 -420,000,000.00 N/A -278,000,000.00 -920,000,000.00 -789,000,000.00 -611,000,000.00 -604,000,000.00 N/A N/A -595,000,000.00
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes N/A 3,003,000,000.00 4,153,000,000.00 2,046,000,000.00 N/A 847,000,000.00 N/A 25,000,000.00 N/A 362,000,000.00 N/A N/A N/A N/A N/A
Effect Of Exchange Rate Changes On Cash And Cash Equivalents N/A 16,000,000.00 -445,000,000.00 171,000,000.00 573,000,000.00 850,000,000.00 N/A 834,000,000.00 1,451,000,000.00 574,000,000.00 -216,000,000.00 -238,000,000.00 N/A N/A 326,000,000.00
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes N/A N/A N/A N/A 896,000,000.00 N/A -144,000,000.00 25,000,000.00 -31,000,000.00 N/A 2,611,000,000.00 1,219,000,000.00 N/A N/A -523,000,000.00
Cash and cash equivalents 533,000,000.00 3,552,000,000.00 7,260,000,000.00 9,477,000,000.00 8,729,000,000.00 8,957,000,000.00 9,071,000,000.00 9,816,000,000.00 10,377,000,000.00 9,893,000,000.00 12,288,000,000.00 10,874,000,000.00 14,867,000,000.00 14,867,000,000.00 14,670,000,000.00

Please note that some sums might not add up.

Filings & Publications

  • Consolidated Report 2024 - Q4 English 🇬🇧 Published: 14.05.2024
  • Consolidated Report 2023 - Q4 English 🇬🇧 Published: 06.06.2023
  • Consolidated Report 2022 - Q4 English 🇬🇧
  • Consolidated Report 2021 - Q4 English 🇬🇧

Capital Markets Information

ISIN

DK0010272202

LEI

529900MTJPDPE4MHJ122

Sub-Industry

Biotechnology

Listed Stock Exchange

Nasdaq Copenhagen

Stock Index

OMX Copenhagen 20

Contact Investor Relations Department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.